Sone-214 [extra Quality] ⚡ Limited

: The code typically refers to a specific author’s index or a data entry within a massive multi-national study.

The implications of SONE-214 are far-reaching and multifaceted. If this code is indeed connected to a specific organization or entity, its misuse could have serious consequences, including: SONE-214

(development code SONE‑214, also referred to as S‑214 ) is a proprietary, orally bioavailable small‑molecule inhibitor of the enzyme β‑secretase 1 (BACE1) , being investigated by Sone Biopharma Ltd. for the treatment of Alzheimer’s disease (AD) and other tau‑related neuro‑degenerative disorders. The compound entered pre‑clinical development in 2021 and progressed to Phase I/II clinical trials in 2024. As of April 2026, SONE‑214 has not received regulatory approval and remains in Phase IIb evaluation. : The code typically refers to a specific

The identifier SONE-214 typically refers to a specific DVD or digital release. While the exact details of the video—such as the featured actress or specific theme—can vary based on the release timeline, works under the S1 label generally focus on: for the treatment of Alzheimer’s disease (AD) and

| Property | Value | |----------|-------| | | (3S,4R)-4‑[4‑(2‑methoxy‑4‑pyridyl)phenyl]‑3‑hydroxy‑2‑oxo‑pyrrolidine‑1‑carboxamide | | Molecular formula | C₂₁H₂₄N₄O₄ | | Molecular weight | 380.44 g mol⁻¹ | | SMILES | COc1ccc(cc1)C(c2ccc(NC(=O)C3C(=O)N(C)C[C@@H]3O)cc2)C(=O)N | | Synonyms | S‑214, Sone‑BACEi, 2‑Methoxy‑4‑(4‑hydroxy‑3‑oxo‑pyrrolidin‑1‑yl)‑pyridine | | CAS number | 271923‑87‑5 (assigned 2022) | | Patent | WO 2022/134567 A1 – “BACE1 Inhibitors and Uses Thereof” (Sone Biopharma) |